Triptorelin Acetate

Triptorelin is a synthetic agonist of gonadotropin-releasing hormone (GnRH). It is an approved medicine in many countries, marketed under brand names such as Trelstar, and is used clinically in oncology, gynecology, and pediatric endocrinology.

Its defining pharmacological feature is that continuous administration ultimately suppresses the reproductive hormone axis rather than stimulating it, which underlies most of its approved therapeutic uses.

Triptorelin acts on the pituitary gland in a way that depends heavily on how it is delivered. Key mechanistic themes include:

• An initial flare: early stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), transiently raising sex hormones

• Subsequent down-regulation: with continuous exposure, the pituitary receptors desensitize and hormone output falls

• A contrast with pulsatile GnRH signaling, in which the body normally releases GnRH in bursts to sustain reproductive function

This flare-then-suppression pattern is why continuous triptorelin behaves differently from short, pulsatile administration of agents such as gonadorelin.

As an approved medicine, triptorelin has recognized clinical indications, including advanced prostate cancer (where lowering testosterone is therapeutic), endometriosis, and central precocious puberty. These uses rely on its ability to suppress the reproductive axis after the initial flare.

Separately, triptorelin attracts interest in fertility discussions and within testosterone-replacement (TRT) communities, where its effects on the HPG axis are debated. Such interest is context-dependent and does not change the fact that use should be guided by a qualified clinician and local regulations.

Triptorelin is named explicitly in S2.2.1 of the WADA Prohibited List. The sub-section is headed "Testosterone-stimulating peptides in males" and covers chorionic gonadotrophin (CG), luteinizing hormone (LH), "gonadotrophin-releasing hormone (GnRH, gonadorelin) and its agonist analogues (e.g. buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin and triptorelin)," and kisspeptin and its agonist analogues.

WADA reworded this section for the 2024 List. USADA's explanation of the change states that "WADA has reworded this section to clarify that testosterone-stimulating peptides (previously Gonadotrophin-Releasing Hormone (GnRH) agonist analogs) are prohibited in males, including buserelin, deslorelin, goserelin, histrelin, leuprorelin, nafarelin, and triptorelin" (USADA athlete advisory, 2024 Prohibited List). The rewrite is worth understanding: the category is now defined by effect — raising endogenous testosterone — rather than by receptor pharmacology, which closes the argument that a novel GnRH-axis molecule is not an "agonist analogue."

The sex-specific asymmetry is real and often misread. Triptorelin is prohibited in males only. The mechanism is the reason: a single GnRH-agonist dose produces an initial "flare" — a surge of LH and downstream testosterone — before the sustained receptor occupancy that causes the desensitisation and suppression used therapeutically in prostate cancer and endometriosis. It is the flare, not the suppression, that anti-doping rules target in men. In female athletes the same agent does not raise testosterone meaningfully, and it is not prohibited on that basis. That exemption is not unconditional, though: the 2026 Monitoring Program — the list of substances WADA tracks for "potential patterns of misuse" without prohibiting them — includes "gonadotrophin-releasing hormone (GnRH) analogues in females under 18 years only," in and out of competition. Monitoring findings do not produce sanctions, but they are how prohibited-list changes usually begin.

Because triptorelin has genuine approved indications, use in a female athlete or a male athlete with a documented clinical need runs through the therapeutic use exemption process rather than through the prohibition.

Reported effects commonly relate to low sex-hormone states, including hot flashes, changes in bone density with prolonged use, mood changes, and reduced libido. The initial flare can also transiently worsen hormone-sensitive conditions, which is a recognized clinical consideration.

Because triptorelin meaningfully alters endocrine function, it requires medical supervision, appropriate monitoring, and careful attention to the specific clinical situation. High-level summaries cannot replace individualized care.

Triptorelin is typically formulated as long-acting depot preparations designed to maintain continuous exposure, which is what drives sustained suppression after the flare. This delivery strategy is the opposite of the brief, pulsatile signaling used to stimulate the axis.

This information summarizes conceptual pharmacology and does not constitute medical advice.

Every marketed triptorelin product is a depot. That is the whole design: the molecule is formulated into lyophilized microgranules that release slowly from an intramuscular injection site, because sustained exposure is what produces the suppression these drugs are prescribed for.

• Trelstar (triptorelin pamoate) — 3.75 mg every 4 weeks, 11.25 mg every 12 weeks, or 22.5 mg every 24 weeks, by single intramuscular injection into either buttock, reconstituted only in sterile water (Trelstar prescribing information).

• Triptodur (triptorelin, extended-release) — a single 22.5 mg intramuscular injection once every 24 weeks, for central precocious puberty in children two and older (Triptodur prescribing information).

The Trelstar label states that because the strengths have different release characteristics, "the dosage strengths are not additive and must be selected based upon the desired dosing schedule." A 22.5 mg depot is not six 3.75 mg doses; it is a differently engineered product. The suspension also has to be injected within two minutes of reconstitution, which is a formulation constraint rather than a clinical preference.

Each depot produces the same characteristic curve. Serum testosterone rises first, peaking around day 2 to 4 depending on strength, then falls to levels typical of surgically castrated men — under 50 ng/dL — within about four weeks, and stays there while the depot lasts. Those effects are usually reversible after treatment stops.

Triptorelin is not stacked with the stimulatory agents it is often listed beside. Gonadorelin and hCG push the reproductive axis up; continuous triptorelin shuts it down. Combining them is not a synergy, it is a contradiction.

Triptorelin has a substantial evidence base tied to its approved indications, including oncology and gynecology trials that established its role in suppressing sex-hormone production. This makes it far better characterized than most experimental peptides.

At the same time, the fertility and TRT-related uses discussed in some communities are less rigorously supported and often extrapolate from its mechanism rather than from dedicated controlled trials. Evidence strength varies sharply by context and should be appraised accordingly.

For deeper dives on this peptide, see:

• Triptorelin areas of interest
• Triptorelin side effects and safety context
• Triptorelin pharmacology concepts (educational)
• Triptorelin research and evidence overview

Why does triptorelin suppress hormones when GnRH stimulates them? Because it never stops signalling. Natural GnRH arrives in bursts and the pituitary responds to that rhythm. Triptorelin is engineered to resist breakdown and is delivered from a depot, so the receptor is occupied continuously — and continuous occupancy causes desensitisation and down-regulation instead of activation. The label describes the sequence directly: an initial transient surge in LH, FSH, testosterone, and estradiol, then, usually 2 to 4 weeks after starting, a sustained fall in LH and FSH and a marked reduction in testicular steroidogenesis (Trelstar prescribing information).

What is triptorelin approved for? In the US, two distinct things. Trelstar is indicated for the treatment of advanced prostate cancer, where lowering testosterone to castrate levels is the therapeutic goal. Triptodur is indicated for central precocious puberty in children two years and older, given as a single 22.5 mg intramuscular injection once every 24 weeks (Triptodur prescribing information). Other GnRH-agonist indications such as endometriosis are handled by different products or in different jurisdictions.

What is the "flare" and why does it matter? It is the first-week testosterone surge before suppression takes hold, and in prostate cancer it can make things temporarily worse. Mean testosterone rises above baseline during the first week following the initial injection, declining to baseline or below by the end of the second week. The label warns that this can worsen signs and symptoms — bone pain, neuropathy, hematuria, urethral or bladder outlet obstruction — and that spinal cord compression with weakness or paralysis of the lower extremities has occurred, which is why patients with metastatic vertebral lesions or urinary obstruction are monitored closely at initiation.

Why is triptorelin prohibited for male athletes but not female athletes? Because the anti-doping rule targets the flare, not the suppression. In men, a GnRH agonist dose produces a surge of LH and downstream testosterone; in women it does not raise testosterone meaningfully. WADA reworded the category for the 2024 List around that effect, naming triptorelin explicitly under "testosterone-stimulating peptides in males" in S2.2.1 of the Prohibited List. The exemption for women is not unconditional — GnRH analogues in females under 18 sit on the 2026 Monitoring Program, which is usually how listing changes begin.

Does a single triptorelin dose restart the HPG axis? This is a common claim in post-cycle discussions and it is not supported by triptorelin's approved evidence base, all of which concerns sustained suppression rather than recovery. The label's own pharmacology runs the other way: chronic administration suppresses the pituitary-gonadal axis, and diagnostic tests of pituitary-gonadal function performed during or after treatment may be misleading. Extrapolating a restart protocol from a suppression drug is an inference about mechanism, not a finding from a trial.

What side effects come with it? Mostly the predictable consequences of a low-sex-hormone state — hot flashes, reduced libido, mood changes, and bone density loss with prolonged use. The label also carries warnings for metabolic syndrome (hyperglycemia, diabetes, hyperlipidemia, non-alcoholic fatty liver disease), increased risk of myocardial infarction, sudden cardiac death and stroke, and QT prolongation, plus reports of anaphylactic shock and angioedema. Testosterone is monitored to confirm castrate levels are reached and maintained.

Is triptorelin the same class as gonadorelin? Same receptor, opposite outcome. Gonadorelin is native GnRH — ten residues, cleared within minutes, and stimulatory when delivered in pulses. Triptorelin is a protease-resistant analogue formulated as a long-acting depot, which is precisely what converts the same receptor interaction into shutdown. Any comparison between them that ignores delivery pattern will get the direction of the effect backwards.